報價延遲最少15分鐘:2025/11/19 07:44 EST
盤前時段
|
||||
|
5.92 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.92
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.74/0.77
|
|
企業價值
124.12M
|
| 資產負債 |
|
每股賬面淨值
1.74
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
0.08
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/11/19 07:44 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent beingdeveloped for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494. |
